RECHEM
Welcome to our website!|Hot Line: 86-21-61417495|E-mail: sales@rechemscience.com
Products Category
Contact Us
Tel: +86-21-61417495
Fax: +86-21-61417495
Email: sales@rechemscience.com
  info@rechemscience.com
QQ: 1369748377
Skype: sales@rechemscience.com
Home > Products > Intermediates
Cat.No. Product name Product Description
R10157 AZD9291 Intermediate1 Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
R10158 AZD9291 Intermediate2 Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
R10261 CDC0032 Intermediate
R10275 Omarigliptin; MK3102 Intermediate1 Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor wit
R10276 Omarigliptin; MK3102 Intermediate2 Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor wit
R10277 AZD9291Intermediate3 Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
R10278 AZD9291Intermediate4 Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
R10279 AZD9291Intermediate5 Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
R10280 CAL101 Intermediate1 CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
R10281 CAL101 Intermediate2 CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
R10282 CAL101 Intermediate3 CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
R10284 Nintedanib; BIBF1120 Intermediate2 Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3,
R10285 Nintedanib; BIBF1120 Intermediate3 Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3,
R10286 Nintedanib; BIBF1120 Intermediate4 Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3,
R10289 TR700; DA7157; Torezolid Intermediate1 Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti
R10290 TR700; DA7157; Torezolid Intermediate2 Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti
R10291 TR700; DA7157; Torezolid Intermediate3 Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti
R10292 TR700; DA7157; Torezolid Intermediate4 Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti
R10293 TR700; DA7157; Torezolid Intermediate5 Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti
R10294 TR700; DA7157; Torezolid Intermediate6 Torezolid (TR-701; tedizolid) is a novel oxazolidinone for gram-positive infecti
R10297 Afatinib BIBW2992 Intermediate1 Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85
R10298 Afatinib BIBW2992 Intermediate2 Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85
R10299 Afatinib BIBW2992 Intermediate3 Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85
R10300 Afatinib BIBW2992 Intermediate4 Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85
R10301 Afatinib BIBW2992 Intermediate5 Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L85
Page 1 / Total 9 FirstPrevNextLastGoto